Published in Circ Res on August 31, 2001
Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest (2003) 3.19
The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol (2005) 3.09
Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation (2007) 2.06
Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity (2009) 1.95
Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens (2010) 1.43
Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol Histopathol (2005) 1.32
Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J (2003) 1.28
CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation (2005) 1.27
The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer (2007) 1.20
Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin (2013) 1.02
Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis (2005) 1.01
Vascular effects of the red blood cell storage lesion. Hematology Am Soc Hematol Educ Program (2011) 1.01
Touch of chemokines. Front Immunol (2012) 1.00
The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J Clin Invest (2003) 0.98
Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood (2007) 0.97
Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells. J Virol (2004) 0.96
Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J Immunol (2013) 0.95
Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One (2012) 0.93
Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation. Br J Pharmacol (2003) 0.89
An oxidized lipid-peroxisome proliferator-activated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesion. Trends Cardiovasc Med (2007) 0.89
Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells. Immunology (2011) 0.89
The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol Biol (2013) 0.87
Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm (2014) 0.87
Syk regulates multiple signaling pathways leading to CX3CL1 chemotaxis in macrophages. J Biol Chem (2011) 0.87
Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease. J Immunol Res (2014) 0.85
Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metalloproteases. J Biol Chem (2009) 0.85
Patients with insulin-dependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects. Vasc Health Risk Manag (2009) 0.84
Greater fractalkine expression in mesenteric arteries of female spontaneously hypertensive rats compared with males. Am J Physiol Heart Circ Physiol (2009) 0.82
Search for an association between V249I and T280M CX3CR1 genetic polymorphisms, endothelial injury and preeclampsia: the ECLAXIR study. PLoS One (2009) 0.82
Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis: a meta-analysis. Dis Markers (2014) 0.81
Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina. ASN Neuro (2015) 0.81
Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression. Cardiovasc Res (2015) 0.80
Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) (2012) 0.80
Ly6Chigh Monocytes Protect against Kidney Damage during Sepsis via a CX3CR1-Dependent Adhesion Mechanism. J Am Soc Nephrol (2015) 0.80
Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis. Mol Med Rep (2015) 0.80
Circulating fractalkine levels predict the development of the metabolic syndrome. Int J Endocrinol (2014) 0.80
Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients. Clin Transl Med (2014) 0.79
CX3CR1 receptor polymorphisms, Th1 cell recruitment, and acute myocardial infarction outcome: looking for a link. Biomed Res Int (2013) 0.77
Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. Int J Colorectal Dis (2007) 0.77
Common and Rare Genetic Variation in CCR2, CCR5, or CX3CR1 and Risk of Atherosclerotic Coronary Heart Disease and Glucometabolic Traits. Circ Cardiovasc Genet (2016) 0.76
A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. AIDS Res Ther (2013) 0.76
Genetic variants in platelet factor 4 modulate inflammatory and platelet activation biomarkers. Circ Cardiovasc Genet (2012) 0.75
TLR4-dependent internalization of CX3CR1 aggravates sepsis-induced immunoparalysis. Am J Transl Res (2016) 0.75
Cytokine receptor CX3CR-1 and fractalkine: new factors in the atherosclerosis drama? Circ Res (2001) 0.75
Effects on serum fractalkine by diet and omega-3 fatty acid intervention: relation to clinical outcome. Mediators Inflamm (2015) 0.75
Association of chemokine receptor CX3CR1 V249I and T280M polymorphisms with chronic kidney disease. Indian J Nephrol (2016) 0.75
Inflammatory Function of CX3CR1+ CD8+ T Cells in Treated HIV Infection Is Modulated by Platelet Interactions. J Infect Dis (2016) 0.75
Downregulation of CX3CR1 ameliorates experimental colitis: evidence for CX3CL1-CX3CR1-mediated immune cell recruitment. Int J Colorectal Dis (2016) 0.75
Synergistic modulation of inflammatory but not metabolic effects of high-fat feeding by CCR2 and CX3CR1. Obesity (Silver Spring) (2017) 0.75
An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol (1988) 26.07
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J (1991) 6.13
Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med (1990) 5.91
Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med (1991) 3.80
A measure of emotional empathy. J Pers (1972) 3.51
Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med (1996) 3.40
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood (2001) 2.87
Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med (1994) 2.80
Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med (1997) 2.79
Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials (2000) 2.67
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol (2000) 2.61
Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol (1996) 2.49
Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp Med (1993) 2.49
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet (1998) 2.45
Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood flow in humans. Proc Natl Acad Sci U S A (2000) 2.41
Genetic polymorphism in CX3CR1 and risk of HIV disease. Science (2000) 2.38
Testing the raters: inter-rater reliability of standardized anaesthesia simulator performance. Can J Anaesth (1997) 2.37
Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem (1994) 2.34
Monoclonal antibodies against a specific surface determinant on malarial (Plasmodium knowlesi) merozoites block erythrocyte invasion. J Immunol (1981) 2.33
A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med (1999) 2.32
Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A (2000) 2.23
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2.21
Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med (1999) 2.20
Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease. JAMA (1997) 2.17
Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. J Biol Chem (1993) 2.08
Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. J Biol Chem (1995) 2.08
Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol (2000) 2.05
Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem (1996) 2.04
Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest (2001) 2.03
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology (1997) 2.02
Racial divergence in adiposity during adolescence: The NHLBI Growth and Health Study. Pediatrics (2001) 2.00
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab (2014) 1.99
Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation (1993) 1.90
Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol (2000) 1.86
Cardiac sympathetic nerve function in congestive heart failure. Circulation (1996) 1.84
Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care (1998) 1.83
Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation (1993) 1.81
Molecular mimicry and the generation of host defense protein diversity. Cell (1993) 1.78
Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem (1995) 1.75
The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol (2000) 1.75
Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science (2000) 1.70
CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci U S A (1996) 1.68
Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation (1994) 1.66
The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis (2000) 1.66
Oral L-arginine in patients with coronary artery disease on medical management. Circulation (2000) 1.65
Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. Circulation (1994) 1.65
Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem (1998) 1.64
Endothelial progenitor cells as putative targets for angiostatin. Cancer Res (1999) 1.63
Role of nitric oxide in the vasodilator response to mental stress in normal subjects. Am J Cardiol (1997) 1.61
Overweight, fat patterning, and cardiovascular disease risk factors in black and white girls: The National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr (1999) 1.60
Impact of aortic stenting on peripheral vascular function and daytime systolic blood pressure in adult coarctation. Heart (2007) 1.59
Morphology of ambulatory ST segment changes in patients with varying severity of coronary artery disease. Investigation of the frequency of nocturnal ischaemia and coronary spasm. Br Heart J (1985) 1.58
Inability of the ST segment/heart rate slope to predict accurately the severity of coronary artery disease. Br Heart J (1984) 1.56
Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol (1992) 1.55
The human genes for GM-CSF and IL 3 are closely linked in tandem on chromosome 5. Blood (1988) 1.54
Stroke prevention trial in sickle cell anemia. Control Clin Trials (1998) 1.53
Prediction of the frequency and duration of ambulatory myocardial ischemia in patients with stable coronary artery disease by determination of the ischemic threshold from exercise testing: importance of the exercise protocol. J Am Coll Cardiol (1991) 1.52
Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309. J Exp Med (1997) 1.47
Surgical treatment of spinal cord astrocytomas of childhood. A series of 19 patients. J Neurosurg (1982) 1.46
Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med (1999) 1.46
National trends in the management of cardiovascular disease risk factors in children: second NHLBI survey of primary care physicians. Pediatrics (1998) 1.46
Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest (1997) 1.46
Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci (2001) 1.45
Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation (1994) 1.45
Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS (2000) 1.44
Incidence of spasm at the site of previous successful transluminal coronary angioplasty: effect of ergometrine maleate in consecutive patients. Br Heart J (1986) 1.43
Freeze-fracture study on the erythrocyte membrane during malarial parasite invasion. J Cell Biol (1981) 1.42
Mechanisms of nocturnal angina pectoris: importance of increased myocardial oxygen demand in patients with severe coronary artery disease. Lancet (1984) 1.41
Identification of surface proteins on viable Plasmodium knowlesi merozoites. J Protozool (1981) 1.39
ACTINOMYCOSIS: REPORT OF CASES. Cal West Med (1929) 1.39
Acute vascular effects of estrogen in postmenopausal women. Circulation (1994) 1.39
Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol (1997) 1.39
Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension (1997) 1.38
Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr Opin Microbiol (2000) 1.38
Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation (1995) 1.38
C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol (1996) 1.37
Identification of a mouse eosinophil receptor for the CC chemokine eotaxin. Biochem Biophys Res Commun (1996) 1.36
Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse. Genomics (1998) 1.36
The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation (1993) 1.36
Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol. Br Med J (Clin Res Ed) (1984) 1.35
CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol (1998) 1.35
Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol (2001) 1.35
Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics (1995) 1.32
Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med (1988) 1.31